Rates of colorectal cancer have been climbing in young people for a couple decades—recent reports from the American Cancer Society (ACS) have pinned it as the leading or second-leading cause of cancer ...
Amy Maxson felt like she was in the best shape of her life, until she couldn't catch her breath. A CT scan revealed it was ...
Breakthrough studies in hematopathology — including advances in genetic testing, relapse prediction and detection of hidden, disease-defining gene fusions in AML — will be presented at the ...
Frederick L. Locke, MD, chair in the department of blood and marrow transplant and cellular immunotherapy at Moffitt Cancer ...
When Amanda Wlezen learned her cousin carried the cancer-causing BRCA2, she decided to go to OSF for genetic testing.
A cancer patient is sounding the alarm about insurance company business dealings that she said put her life and thousands of ...
Bill Arneson of Moffitt Cancer Center explains how an AI tool for medical necessity appeals cut the cost to work a claim from $50 to $5, helping his team recover $500,000 in claims that would have ...
In an interview with Targeted Oncology, Frederick L. Locke, MD, discussed how the elimination of the REMS program for CAR T-cell therapy came about and what effects he hopes this will have on patient ...
Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic ...
Dr. Strosberg discusses the safety profile and long-term toxicities of 212Pb-DOTAMTATE treatment, highlighting renal issues ...
NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) announced that clinical data on rusfertide in polycythemia vera, including the ...
Researchers at Moffitt Cancer Center have developed a novel biomaterial-based system that induces the formation of tertiary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback